Miguel‐Teodoro Hernández

6.1k total citations
44 papers, 1.2k citations indexed

About

Miguel‐Teodoro Hernández is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Miguel‐Teodoro Hernández has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 22 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Miguel‐Teodoro Hernández's work include Multiple Myeloma Research and Treatments (30 papers), Protein Degradation and Inhibitors (12 papers) and Cancer Treatment and Pharmacology (8 papers). Miguel‐Teodoro Hernández is often cited by papers focused on Multiple Myeloma Research and Treatments (30 papers), Protein Degradation and Inhibitors (12 papers) and Cancer Treatment and Pharmacology (8 papers). Miguel‐Teodoro Hernández collaborates with scholars based in Spain, Italy and France. Miguel‐Teodoro Hernández's co-authors include Jesús F. San Miguel, Juan José Lahuerta, Javier de la Rubia, Laura Rosiñol, Joan Bladé, María‐Victoria Mateos, Albert Oriol, Felipe de Arriba, Bruno Paiva and Joan Bargay and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Miguel‐Teodoro Hernández

41 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miguel‐Teodoro Hernández Spain	14	796	597	544	210	165	44	1.2k
Marta Krejčí Czechia	17	832 1.0×	497 0.8×	574 1.1×	190 0.9×	118 0.7×	155	1.3k
A. John Ashcroft United Kingdom	16	949 1.2×	663 1.1×	913 1.7×	156 0.7×	105 0.6×	23	1.5k
Eurydiki Michalis Greece	13	516 0.6×	429 0.7×	341 0.6×	284 1.4×	181 1.1×	24	858
E Jacky Switzerland	15	882 1.1×	287 0.5×	314 0.6×	173 0.8×	156 0.9×	25	1.3k
Ángel León Spain	14	1.1k 1.4×	687 1.2×	405 0.7×	253 1.2×	328 2.0×	21	1.6k
M. L. Vegna Italy	14	765 1.0×	517 0.9×	296 0.5×	218 1.0×	186 1.1×	20	1.2k
Anne Marie Stoppa France	18	844 1.1×	555 0.9×	322 0.6×	196 0.9×	124 0.8×	43	1.2k
Athanasios Zomas Greece	18	852 1.1×	502 0.8×	443 0.8×	366 1.7×	303 1.8×	55	1.3k
Brigitte Pegourié France	16	1.6k 2.0×	1.1k 1.9×	909 1.7×	310 1.5×	88 0.5×	49	1.7k
S. Faderl United States	16	882 1.1×	417 0.7×	240 0.4×	393 1.9×	97 0.6×	24	1.2k

Countries citing papers authored by Miguel‐Teodoro Hernández

Since Specialization

Citations

This map shows the geographic impact of Miguel‐Teodoro Hernández's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel‐Teodoro Hernández with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel‐Teodoro Hernández more than expected).

Fields of papers citing papers by Miguel‐Teodoro Hernández

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel‐Teodoro Hernández. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel‐Teodoro Hernández. The network helps show where Miguel‐Teodoro Hernández may publish in the future.

Co-authorship network of co-authors of Miguel‐Teodoro Hernández

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel‐Teodoro Hernández. A scholar is included among the top collaborators of Miguel‐Teodoro Hernández based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel‐Teodoro Hernández. Miguel‐Teodoro Hernández is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hernández, Miguel‐Teodoro, et al.. (2025). Comparative Evaluation of the Intratubular Penetration Ability of Two Retrograde Obturation Techniques in Micro-Endodontic Surgical Procedure: An In Vitro Study with Confocal Laser Scanning Microscopy. Dentistry Journal. 13(11). 509–509.

Hernández, Miguel‐Teodoro, et al.. (2023). Brain abscess as an otorhinolaryngological complication. SHILAP Revista de lepidopterología. 24(3). 260–266. 1 indexed citations

Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Javier de la Rubia, et al.. (2022). Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. European Journal of Cancer. 174. 243–250. 19 indexed citations

Gamberi, Barbara, Christian Berthou, Miguel‐Teodoro Hernández, et al.. (2020). A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. Clinical Lymphoma Myeloma & Leukemia. 20(10). e629–e644. 1 indexed citations

Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2016). Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. The Lancet Oncology. 17(8). 1127–1136. 107 indexed citations

Gamberi, Barbara, Miguel‐Teodoro Hernández, Christian Berthou, et al.. (2016). European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib. Blood. 128(22). 3331–3331.

Mateos, María‐Victoria, Albert Oriol, Joaquín Martínez‐López, et al.. (2016). Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma. British Journal of Haematology. 175(3). 448–456. 39 indexed citations

García‐Sánz, Ramón, Albert Oriol, María José Moreno, et al.. (2015). Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica. 100(9). 1207–1213. 24 indexed citations

Rosiñol, Laura, Ana Isabel Teruel, Javier de la Rubia, et al.. (2015). Characteristics and Outcome of 66 Patients with Extramedullary Plasmacytomas (EMPs) Included in a Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM). Clinical Lymphoma Myeloma & Leukemia. 15. S52–S52. 1 indexed citations

10.

Mayans, J, Inmaculada Castillo, Manuel Jurado, et al.. (2015). Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy. European Journal Of Haematology. 96(4). 417–424. 1 indexed citations

11.

Rosiñol, Laura, Albert Oriol, María Jesús Blanchard, et al.. (2014). Tumor and Renal Response in Patients with Newly Diagnosed Multiple Mieloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM. Blood. 124(21). 4776–4776. 1 indexed citations

12.

Paiva, Bruno, Noemí Puig, María‐Belén Vídriales, et al.. (2014). Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance. Blood. 124(21). 25–25. 1 indexed citations

13.

Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2013). Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 369(5). 438–447. 348 indexed citations

14.

Matarraz, Sergio, Bruno Paiva, María Díez‐Campelo, et al.. (2012). Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?. Haematologica. 97(10). 1608–1611. 12 indexed citations

15.

García‐Sánz, Ramón, Albert Oriol, Javier de la Rubia, et al.. (2012). Analysis of Zoledronic ACID Therapy for Patients with Multiple Myeloma with Asymptomatic Biochemical Relaps.. Blood. 120(21). 2967–2967. 1 indexed citations

16.

Montalbán, Carlos, Víctor Abraira, Luca Arcaini, et al.. (2011). Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System. Blood. 118(21). 1583–1583. 2 indexed citations

17.

Sarasquete, María Eugenia, Ramón García‐Sánz, Luis Marı́n, et al.. (2008). Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 112(7). 2709–2712. 164 indexed citations

18.

Rosiñol, Laura, Josè Antonio Pérez-Simón, Anna Sureda, et al.. (2008). A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 112(9). 3591–3593. 172 indexed citations

19.

Sanz, Emílio J., Miguel‐Teodoro Hernández, Maryse Lapeyre‐Mestre, et al.. (2005). Prescribers' indications for drugs in childhood: A survey of five European countries (Spain, France, Bulgaria, Slovakia and Russia). Acta Paediatrica. 94(12). 1784–1790. 9 indexed citations

20.

Vidal-Aragón, M. C., Miguel‐Teodoro Hernández, E. Sabio, & M.J. Bernalte. (1996). Identificación de la fracción volátil de cereza de la variedad Ambrunés almacenada en PVC. Alimentaria. 69–72. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact